STRATA Skin Sciences (SSKN) Cash & Equivalents (2010 - 2025)

STRATA Skin Sciences has disclosed Cash & Equivalents across 16 years of filings, most recently posting $7.9 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $7.9 million, up 8.97% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.9 million (up 8.97% YoY), and the FY2025 annual result was $7.9 million, up 8.97% from the prior year.
• Cash & Equivalents came in at $7.9 million for Q4 2025 at STRATA Skin Sciences, up from $7.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.0 million in Q3 2021 to a low of $2.8 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $7.2 million (2023), against an average of $7.9 million.
• Across the five-year window, Cash & Equivalents slumped 74.14% in 2023 and soared 85.38% in 2024, its largest moves.
• STRATA Skin Sciences' Cash & Equivalents stood at $12.6 million in 2021, then sank by 56.83% to $5.4 million in 2022, then grew by 24.84% to $6.8 million in 2023, then grew by 7.03% to $7.3 million in 2024, then rose by 8.97% to $7.9 million in 2025.
• The last three Cash & Equivalents figures came in at $7.9 million (Q4 2025), $7.1 million (Q3 2025), and $6.0 million (Q2 2025), per Business Quant data.